Regeneron declines to make higher bid for 23andMe after Wojcicki’s $305 million offer
-Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning bid of ...
Read moreDetails-Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning bid of ...
Read moreDetails
